ITEM 8.01. Other Events

Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company developing monoclonal antibodies that target various cancer types, issued a press release on January 25, 2023 announcing the completion of the dosing period of its Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for brain cancer.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

ITEM 9.01. Financial Statements and Exhibits





Exhibit No.   Description
  99.1*         Press Release, dated January 25, 2023
104*          Cover Page Interactive Data File (formatted as Inline XBRL and
              contained in Exhibit 101)




*Furnished herewith




2

© Edgar Online, source Glimpses